Cargando…

Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled phase III study in Asian patients

AIMS/INTRODUCTION: This study evaluated the efficacy and safety of mirogabalin, a novel, potent, selective ligand of the α(2)δ subunit of voltage‐dependent Ca(2+) channels, for the treatment of diabetic peripheral neuropathic pain (DPNP). MATERIALS AND METHODS: During this double‐blind, multisite, p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baba, Masayuki, Matsui, Norimitsu, Kuroha, Masanori, Wasaki, Yosuke, Ohwada, Shoichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717827/ https://www.ncbi.nlm.nih.gov/pubmed/30672128 http://dx.doi.org/10.1111/jdi.13013

Ejemplares similares

Long‐term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain
por: Baba, Masayuki, et al.
Publicado: (2019)

Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study
por: Baba, Masayuki, et al.
Publicado: (2020)

Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients
por: Kato, Jitsu, et al.
Publicado: (2019)

Mirogabalin in Japanese Patients with Renal Impairment and Pain Associated with Diabetic Peripheral Neuropathy or Post-Herpetic Neuralgia: A Phase III, Open-Label, 14-Week Study
por: Baba, Masayuki, et al.
Publicado: (2020)

Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial
por: Kato, Jitsu, et al.
Publicado: (2020)

Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia
por: Ushida, Takahiro, et al.
Publicado: (2023)

Therapeutic Effect of Mirogabalin on Peripheral Neuropathic Pain due to Lumbar Spine Disease
por: Kim, Kyongsong, et al.
Publicado: (2021)

Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study
por: Tetsunaga, Tomoko, et al.
Publicado: (2020)

Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia
por: Ushida, Takahiro, et al.
Publicado: (2023)

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies
por: Brown, Karen, et al.
Publicado: (2018)

Mirogabalin, a selective gabapentinoid for managing neuropathic pain—A curtain raiser
por: Nair, Abhijit
Publicado: (2022)

The Clinical Application and Progress of Mirogabalin on Neuropathic Pain as a Novel Selective Gabapentinoids
por: Tang, Hui, et al.
Publicado: (2023)

Frequency of Adverse Drug Reactions and Analgesic Effects of Mirogabalin during Treatment of Peripheral Neuropathic Pain: A Retrospective Clinical Investigation
por: Inage, Kazuhide, et al.
Publicado: (2020)

Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study
por: Nikaido, Takuya, et al.
Publicado: (2022)

Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study
por: Li, Yi, et al.
Publicado: (2023)

Correction to: Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study
por: Nikaido, Takuya, et al.
Publicado: (2022)

Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients
por: Sugimoto, Mitsuru, et al.
Publicado: (2021)

Switching From Pregabalin to Mirogabalin in Patients with Peripheral Neuropathic Pain: A Multi-Center, Prospective, Single-Arm, Open-Label Study (MIROP Study)
por: Kimura, Yoshiyuki, et al.
Publicado: (2021)

Mirogabalin and emerging therapies for diabetic neuropathy
por: Javed, Saad, et al.
Publicado: (2018)

Mirogabalin Decreases Pain-like Behaviours and Improves Opioid and Ketamine Antinociception in a Mouse Model of Neuropathic Pain
por: Zajączkowska, Renata, et al.
Publicado: (2022)

Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin
por: Yamanaka, Takuya, et al.
Publicado: (2022)

Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin: A Novel Case Report
por: Saito, Yoshitaka, et al.
Publicado: (2022)

Abuse potential of mirogabalin in recreational polydrug users
por: Mendell, Jeanne, et al.
Publicado: (2019)

A Probable Case of Mirogabalin-Induced Neutropenia
por: Takahashi, Saeko, et al.
Publicado: (2020)

Mirogabalin: could it be the next generation gabapentin or pregabalin?
por: Kim, Jae-Yeon, et al.
Publicado: (2021)

Somnolence and Dizziness During Mirogabalin Treatment in Patients With Neuropathic Pain Related to Lumbar Disease Who Switched From Pregabalin: A Retrospective Study
por: Akazawa, Tsutomu, et al.
Publicado: (2021)

Efficacy and safety evaluation of pregabalin treatment over 52 weeks in patients with diabetic neuropathic pain extended after a double‐blind placebo‐controlled trial
por: Satoh, Jo, et al.
Publicado: (2011)

Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo
por: Gao, Y, et al.
Publicado: (2015)

Efficacy of pregabalin in post-traumatic peripheral neuropathic pain: a randomized, double-blind, placebo-controlled phase 3 trial
por: Markman, John, et al.
Publicado: (2018)

Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study protocol for a multicenter, randomized, open-label, parallel-group, interventional trial
por: Doi, Ryoichiro, et al.
Publicado: (2021)

Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study)
por: Misawa, Sonoko, et al.
Publicado: (2023)

A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain
por: Ziegler, Dan, et al.
Publicado: (2015)

The effect of Neuragen PN(® )on Neuropathic pain: A randomized, double blind, placebo controlled clinical trial
por: Li, Li
Publicado: (2010)

Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer
por: Wang, De‐shen, et al.
Publicado: (2019)

Rationale and design of Diabetes Prevention with active Vitamin D (DPVD): a randomised, double-blind, placebo-controlled study
por: Kawahara, Tetsuya, et al.
Publicado: (2016)

Cannabis-Based Medicine for Neuropathic Pain and Spasticity—A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial
por: Hansen, Julie Schjødtz, et al.
Publicado: (2023)

Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials
por: Yen, Chia-Jui, et al.
Publicado: (2018)

Mirogabalin—A Novel Selective Ligand for the α2δ Calcium Channel Subunit
por: Zajączkowska, Renata, et al.
Publicado: (2021)

Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence
por: Chen, Eric Y., et al.
Publicado: (2021)

Effects of Mirogabalin on Hyperalgesia and Chronic Ocular Pain in Tear-Deficient Dry-Eye Rats
por: Kikuchi, Kasumi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q7p953hbf0to6p119t6submmqe